Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration
News Oct 31, 2014
Foundation Medicine, Inc. and WuXi PharmaTech (Cayman) Inc. have announced a collaboration to offer Foundation Medicine's comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China.
Under the terms of the collaboration, Foundation Medicine will license and enable WuXi to perform the laboratory component of Foundation Medicine's FoundationOne® assay at the WuXi Genome Center in Shanghai, the first and only CLIA-certified laboratory in China.
Foundation Medicine will offer China-based products and services to global biopharmaceutical partners to support their clinical research and development efforts in China. Financial terms of the collaboration are not being disclosed.
"China is poised to become the second-largest pharmaceutical market within the next few years," said Dr. Ge Li, chairman and chief executive officer of WuXi. "WuXi has seen rapidly increasing demand for molecular profiling services from biopharmaceutical companies as they scale up R&D operations and early development activities in the region. We are pleased to partner with Foundation Medicine, the recognized global leader in comprehensive genomic profiling and a trusted partner of our customers, to provide best-in-class genomic testing to support targeted oncology therapeutic development in China."
"WuXi is the recognized leader in providing high-quality R&D services in China to the biopharmaceutical industry," said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. "The development and use of targeted therapies and comprehensive diagnostic tests in oncology are expected to grow significantly in China. WuXi's leadership position in China makes WuXi an ideal partner as Foundation Medicine expands its global reach to support targeted drug development and clinical entry into this rapidly growing market."
Foundation Medicine is working with more than 20 biopharmaceutical companies to provide comprehensive genomic profiling in more than 100 studies in 2014 alone. Publicly announced research partners include AstraZeneca, Eisai, Johnson & Johnson, Novartis, and Sanofi.
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Revolutionary Imaging Technique Uses CRISPR to Map DNA MutationsNews
The new high-speed AFM method can map DNA to a resolution of tens of base pairs while creating images up to a million base pairs in size. And it does it using a fraction of the amount of specimen required for DNA sequencing.READ MORE